IL13 and Alzheimer disease: Lebrikizumab, a humanized monoclonal IgG4 antibody that selectively blocks IL13 and prevents the heterodimerization of the type II IL4R receptor composed of IL4Rα and IL13Rαl subunits (Figure 3b) [77], already established its safety and efficacy in AD.